Krystal Biotech exceeds sales and earnings forecasts; publishes outlook for the 2026 financial year

$KRYS (+1,89%)

Here, too, I remain invested.

Fourth quarter GAAP earnings per share of $1.70 beat expectations by $0.29 .

Sales of USD 107.1 million (+17.6% compared to the previous year) exceeded expectations by USD 1.97 million .

https://seekingalpha.com/news/4552381-krystal-biotech-beats-top-line-and-bottom-line-estimates-initiates-fy26-outlook